Navigation Links
Amedica Signs Agreement with Kyocera for Commercial Manufacture of Silicon Nitride Medical Devices
Date:11/26/2013

SALT LAKE CITY, Nov. 26, 2013 /PRNewswire/ -- Amedica Corporation, a biomaterials company, today announced a collaboration with Kyocera Industrial Ceramics Corporation, a worldwide leading ceramics producer, to manufacture medical devices from Amedica's Silicon Nitride biomaterial at Kyocera's Vancouver, WA facility. This collaboration includes the manufacture of Amedica's FDA approved Silicon Nitride spinal interbody devices and will broaden Amedica's ability to meet market demand. 

As a biomaterial, Silicon Nitride has been shown to help promote bone growth and has anti-infective properties. Devices made from Silicon Nitride are semi-radiolucent with clearly visible boundaries enabling an exact view of intraoperative placement and postoperative fusion assessment via common imaging modalities. Amedica believes that these are essential characteristics that surgeons seek when choosing the ideal spinal interbody implant for their patients. Amedica has sold over 14,000 of these devices worldwide.

Eric Olson, President and CEO of Amedica Corporation, says, "There is an unmet need for advanced biomaterials in Orthopedics and Spine. We are seeing an increasing interest for our Silicon Nitride interbody devices and increased interest in this material for use in other applications and want to ensure a consistent supply for surgeons and more importantly, patients. As the world's number one producer of advanced ceramics* with vast experience in ensuring market demand is consistently fulfilled for innovative products, Kyocera is the ideal partner to help broaden availability of our novel biomaterial devices."

About Amedica Corporation

Amedica is a commercial biomaterial company focused on using its Silicon Nitride technology platform to develop, manufacture and sell a broad range of medical devices.  Amedic
'/>"/>

SOURCE Amedica Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Bacterin Signs Distribution Agreement with Jeil for LeForte Craniomaxillofacial System
2. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
3. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
4. The European Union Signs Grant Contract to Fund a 2 Million Euro Biotechnology Research Project Led by Hadassah College Jerusalem
5. Metamark Genetics Signs Collaboration Agreement on Novel Therapeutic Targets with Janssen Biotech
6. Agendia Signs Contract with Blue Shield of California
7. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
8. Volition Signs Collaboration Agreement With Abcodia
9. MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix®
10. Psyche Systems Corporation Signs Strategic Alliance with Siemens Healthcare to Provide Anatomic Pathology Solutions
11. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... -- Donald Fresne, President and CEO of Egenix, Inc. is pleased ... to its Scientific Advisory Committee. Dr. Vagner, a ... , performed research at Embl (European Molecular Biology Laboratory) Heidelberg, ... institute of health and medical research. He is a Research ... Orsay, France , and at the Gustave ...
(Date:9/16/2014)... September 16, 2014 Pharma ... to position themselves for their 89th year ... and encoding, Pharma Packaging Solutions is preparing ... and software and new procedures. Establishing training ... Manufacturing Practices (cGMP), Pharma Packaging Solutions will ...
(Date:9/16/2014)... Denmark , Sept. 16, 2014  Ascendis ... innovative TransCon technology to address significant unmet medical ... ongoing Phase 2 pediatric study to evaluate once-weekly ... deficiency, or GHD.  The full interim results will ... the GRS and IGF Society, being held October ...
(Date:9/16/2014)... RENU 28, the world's first and only skin ... purchase in Australia and New Zealand in mid-August . , ... The tour will make stops in Brisbane on September 16, ... Sydney on the 20th, and Melbourne on the 22nd. , ... and to educate people about the new product and business ...
Breaking Biology Technology:New Appointment to the Scientific Advisory Committee at Egenix, Inc. 2Adding Serialization Capabilities and Expanded Capacity, Pharma Packaging Solutions Is Preparing for 89th Year of Business 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Global Wellness Company Hosts ASEA Australia Tour September 16-22 2
... and improved seizure freedom versus placebo when ... (AEDs)- Phase III study supports recent U.S. ... Jan. 27 The new antiepileptic drug ... adult partial-onset epilepsy patients whose seizures were ...
... Canada, Jan. 27 InNexus Biotechnology Inc. (OTC Bulletin ... today that it has completed a second private placement ... placement that was completed 12 December 2008.The private placement, ... Debenture will be convertible into common shares of InNexus ...
... (CTI),(Nasdaq and MTA: CTIC) announced today that the ... Letter") from the Listing,Qualifications Staff (the "Staff") of ... not comply with Marketplace Rule 4350(i)(1)(C) when the,Company ... ("SMI"),and issued additional common shares to SMI shareholders. ...
Cached Biology Technology:Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 2Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 3Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 4Epilepsia Study Demonstrates New Add-on Antiepileptic Drug Vimpat(R) (lacosamide) Significantly Reduces Partial-Onset Seizures in Adults With Epilepsy 5InNexus Completes Previously Announced Private Placement 2Cell Therapeutics Receives Additional NASDAQ Notification 2Cell Therapeutics Receives Additional NASDAQ Notification 3Cell Therapeutics Receives Additional NASDAQ Notification 4
(Date:9/16/2014)... Philadelphia, PA, September 16, 2014 Schizophrenia is associated ... A growing body of research suggests that the relationship ... effort by patients to use nicotine to self-medicate symptoms ... new study, published in the current issue of ... authors found that the level of nicotine receptors in ...
(Date:9/16/2014)... responsible for practically all vital functions in an ... signals, transport particular substances and control immune system ... do not function independently of each other, but ... the protein networks, you find many similarities with ... TUM,s Chair of Plant Systems Biology. "Some proteins ...
(Date:9/15/2014)... processes from digestion to disease resistance. Despite the fact ... on the planet, more is known about belly-button bacteria ... and colleagues working on Panama,s Barro Colorado Island discovered ... home to more than 400 different kinds of bacteria. ... than 7,000 different kinds. , Bacteria in tropical forests ...
Breaking Biology News(10 mins):Smoking and schizophrenia linked by alterations in brain nicotine signals 2Good networkers make prime targets 2Smithsonian scientists discover tropical tree microbiome in Panama 2
... St. Louis, MO, June 1, 2010 Making food choices ... according to a new study comparing the nutritional content of ... the June issue of the Journal of the American ... diet consisting entirely of advertised foods would contain 25 times ...
... Arbor, Mich. University of Michigan scientists have provided the ... brain that influences the effectiveness of serotonin-related antidepressants, such as ... ahead of print in the journal Proceedings of the ... a more targeted treatment of depression and anxiety with fewer ...
... have identified three new susceptibility genes in a genome-wide ... by the Genome Institute of Singapore (GIS), a biomedical ... Research (A*STAR), and the Sun Yat-Sen University Cancer Centre, ... understanding of the important role played by host genetic ...
Cached Biology News:TV food advertisements promote imbalanced diets 2Animal study reveals new target for antidepressants 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 2Scientists find genes associated with throat cancer through study of over 10,000 subjects 3
... Anti-M13 polyclonal antibody was derived from ... phage particles.Recombinant protein domains such as antibody ... protein pIII and displayed on phage using ... system utilized in the Ph.D. libraries. Anti-M13 ...
...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
This spacer is required to use the Miniature FRENCH Pressure Cell (FA-003) with the Laboratory Press....
Biology Products: